drugset
drugset / Trial / NCT04470622

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

NCT04470622 ↗

Phase 2 Terminated 27 enrolled Heron Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.

Timeline

Start
2020-07-20
Primary completion
2021-04-09
Completion
2021-06-03

Outcome

Outcome not reported

Stopped: “Study was terminated early by Heron, and was not terminated for safety reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified — —

Indications

COVID-19